and Human Services (HHS)
EXPIRED
Participating Organization(s) |
National Institutes of Health (NIH) |
Fogarty International Center (FIC) National Cancer Institute (NCI) National Institute on Alcohol Abuse and Alcoholism (NIAAA) National Institute on Deafness and Other Communication Disorders
(NIDCD) |
|
Funding Opportunity Title |
Limited Competition: Fogarty International Research Collaboration - Behavioral and Social Sciences (FIRCA-BSS) Research Award (R03) |
Activity Code |
|
Announcement Type |
Reissue of PAR-08-223 |
Related Notices |
|
Funding Opportunity Announcement (FOA) Number |
PAR-11-036 |
Companion FOA |
PAR-11-037 , R03 Small Research Grants Program |
Catalog of Federal Domestics Assistance (CFDA) Number(s) |
93.989, 93.399, 93.866, 93.173, 93.121, 93.279, 93.273 |
FOA Purpose |
This Funding Opportunity Announcement (FOA), the Fogarty International Research Collaboration Behavioral and Social Sciences (FIRCA-BSS) Research Award facilitates collaborative behavioral and social sciences research between scientists supported by the National Institutes of Health (NIH) and investigators in low- and middle-income countries (LMICs). Special consideration will be given to proposed research that addresses significant global health problems, particularly those of high relevance to a LMIC or region, and that includes research capacity building as a major aim of the proposed project. |
Posted Date |
November 17, 2010 |
Open Date (Earliest Submission Date) |
December 10, 2010 |
Letter of Intent Due Date |
December 10, 2010 |
Application Due Date(s) |
January 10, 2011, January 10, 2012, January 10, 2013, by 5:00 PM local time of applicant organization. |
AIDS Application Due Date(s) |
Not Applicable. |
Scientific Merit Review |
June/July 2011, June/July 2012, June/July 2013 |
Advisory Council Review |
October 2011, October 2012, October 2013 |
Earliest Start Date(s) |
December 2011, December 2012, December 2013 |
Expiration Date |
(Now Expired April 26, 2012 per NOT-TW-12-008), Original Date January 11, 2013 |
Due Dates for E.O. 12372 |
Not Applicable |
Required Application Instructions
It is critical that applicants follow the instructions in the SF 424 (R&R) Application Guide except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.
Part 1. Overview Information
Part 2. Full Text of the Announcement
Section I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission
Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information
The Fogarty International Center is dedicated to advancing the mission of the National Institutes of Health by supporting and facilitating global health research conducted by U.S. and international investigators, building partnerships between health research institutions in the U.S. and abroad, and training the next generation of scientists to address global health needs. This FOA contributes to the FIC mission, by strengthening research collaborations between NIH funded scientists and scientists in Low-and Middle-Income Countries (LMICs), particularly those with the least economic resources. This FOA responds to a number of goals in the new FIC strategic plan (http://www.fic.nih.gov/about/plan/strategicplan_08-12.htm)
The main objectives of the FIRCA program are to: (1) support collaborative efforts in behavioral and social sciences research between NIH-funded scientists and LMIC scientists (referred to as the LMIC collaborator/PD/PI ) on research of high scientific merit, relevant to global health and of mutual interest and benefit; (2) help achieve Fogarty International Center's strategic plan goals including implementation science, chronic disease, infectious diseases (non-AIDS) and, maternal and child health including the Global Health Initiative (http://www.theglobalhealthinitiative.org/); and (3) help build research capabilities and foster further sustained and productive research and research collaborations at the LMIC institution.
The opportunity to collaborate internationally provides a means of access to new information and perspectives, innovative concepts and methods, emerging research techniques and technologies, and unique populations and environments important for addressing global health problems.
The FIRCA will extend and enhance the research interests of both the NIH-funded scientist and the collaborating LMIC scientist, and will help build the research and research capabilities of the LMIC investigator and institution.
The research capacity building goal of the FIRCA is served by both the direct research collaboration between the teams involved in the research and also by the associated training and consultation at the LMIC site. This training and consultation may also involve other investigators and students at the LMIC site thereby helping to build institutional capacity. The NIH funded PI may spend up to three months of the year under the FIRCA teaching and consulting at the LMIC site. In such case a formal detailed plan with proposed curriculum, audience, schedule and time frame should be presented as part of the research plan.
All non-AIDS-related behavioral and social sciences research topics that are supported by the NIH, and that do not involve basic biomedical research topics are eligible for inclusion under the FIRCA-BSS program. Research topics related to human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS) are not eligible for FIRCA funding. Investigators working on topics related to HIV/AIDS and wishing to conduct collaborative research involving LMICs should note the other opportunities listed at (http://grants.nih.gov/grants/guide/notice-files/NOT-TW-07-002).
Funding Instrument |
Grant |
Application Types Allowed |
New The OER Glossary and the SF 424 (R&R) Application Guide provide details on these application types. |
Funds Available and Anticipated Number of Awards |
The number of awards is contingent upon NIH appropriations, and the submission of a sufficient number of meritorious applications. |
Award Budget |
Budget for direct costs for up to $50,000 per year and project duration of up to three years may be requested for a maximum of $150,000 direct costs over a three year period |
Award Project Period |
The total project period for an application submitted in response to this funding opportunity may not exceed three years. |
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.
Higher Education Institutions:
The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
Nonprofits Other Than Institutions of Higher Education
For profit Organizations
Governments
Other
Foreign (non-U.S.) components of U.S. Organizations are allowed.
The LMIC collaborator/PD/PI must be from an institution located in a LMIC defined by the World Bank, according to Gross National Income (GNI) per capita as low-income, lower-middle-income, and upper-middle-income (see: http://data.worldbank.org/about/country-classifications/country-and-lending-groups). For the purposes of this announcement, Hong Kong and Taiwan are considered high income, and thus not eligible.
LMIC institutions may only apply if they meet the eligibility requirements for LMIC collaborating institutions listed above and the PD/PI and Collaborating Investigators meet the criteria listed below in Section 1.B., Eligible Individuals.
Occasionally, scientific opportunities may arise that warrant a formal collaborative effort between the PD/PI and individuals from more than one country. Such applications may be considered only after consultation with the FIC Program Officer.
Applicant organizations must complete the following registrations
as described in the SF 424 (R&R) Application Guide to be eligible to apply
for or receive an award. Applicants must have a valid Dun and Bradstreet
Universal Numbering System (DUNS) number in order to begin each of the
following registrations.
All Program Directors/Principal Investigators (PD/PIs) must
also work with their institutional officials to register with the eRA Commons
or ensure their existing eRA Commons account is affiliated with the eRA Commons
account of the applicant organization.
All registrations must be completed by the application due date. Applicant
organizations are strongly encouraged to start the registration process at
least four (4) weeks prior to the application due date.
Any individual(s) with the skills, knowledge, and resources
necessary to carry out the proposed research as the Project Director/Principal
Investigator (PD/PI) is invited to work with his/her organization to develop an
application for support. Individuals from underrepresented racial and ethnic
groups as well as individuals with disabilities are always encouraged to apply
for NIH support.
For institutions/organizations proposing multiple PDs/PIs, visit the Multiple
Program Director/Principal Investigator Policy and submission details in the Senior/Key
Person Profile (Expanded) Component of the SF 424 (R&R) Application Guide.
The scientist who applies as the PD/PI must either (1) be an NIH-funded Investigator or (2) have previously been the LMIC collaborator on an awarded FIRCA.
The LMIC collaborator/PD/PI on a FIRCA must be employed at a LMIC institution that meets the eligibility requirements described in Section 1.A., Eligible Institutions.
Applicants may already be FIRCA grantees on another FIRCA at the time of the application. Applicants may submit more than one application, provided that each application is scientifically distinct.
Eligible Funding Mechanisms for Consideration as FIRCA Grants
The following NIH research project grant mechanisms are eligible as FIRCA companion grants (and must be both active and funded at the start of the proposed FIRCA budget period, except for resubmissions):
R01, R37 (MERIT), P01, U01, R03, and R21. PIs of sub-projects of a program project (P01) or cooperative agreement (U01 and U19) are eligible.
Grants reviewed under an FIC's Funding Opportunity Announcement (e.g. the Fogarty International Center (FIC) Ecology of Infectious Diseases (EID) Research Program) but awarded by Institutions/Organizations outside of NIH, are eligible.
Among the mechanisms not generally accepted are: training grants, Small Business Innovation Research (R43/R44) and Small Business Technology Transfer (R41/R42) Awards.
The active funded companion grant may have been awarded by any NIH Institute or Center (IC), regardless of whether the IC is listed as a participating component in this FOA. To be eligible, the grant must have a minimum of 12 months of funding, which may include a no-cost extension, remaining at the time of the initial FIRCA application deadline. For the follow-up application from the LMIC collaborator as PD/PI no active grant for the former FIRCA collaborator is necessary.
The FIRCA research application may be directly (e.g. the specific aims of FIRCA application are closely associated with that of the companion grants) or indirectly (e.g. the specific aims of FIRCA application are not related to that of the companion grant, but the research methods are similar to that of the parent grant) related to the parent grant. The proposed research can be an extension or a new direction of the parent grant research, but it must not overlap with the specific aims and research already supported by the parent grant or by other sources.
To continue the collaboration under the FIRCA program, LMIC collaborators on previously funded FIRCA grants that have ended, or will end before the new FIRCA application deadline, must apply for a FIRCA as PD/PI either with their original FIRCA collaborator or a new collaborator as justified by the needs of the research. Current grantees and collaborators may want to consider whether their collaboration has developed to the point where they can submit a Research Project (R01) grant application (direct foreign grant or domestic grant with a foreign component).
This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
Applicant organizations may submit more than one application,
provided that each application is scientifically distinct.
NIH will not accept any application in response to this FOA that is essentially the same as one currently pending initial peer review unless the applicant withdraws the pending application. NIH will not accept any application that is essentially the same as one already reviewed. Resubmission applications may be submitted, according to the NIH Policy on Resubmission Applications from the SF 424 (R&R) Application Guide.
Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the Apply for Grant Electronically button in this FOA or following the directions provided at Grants.gov.
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:
Descriptive title of proposed research
Name, address, and telephone number of the PD(s)/PI(s)
Names of other key personnel
Participating institutions
Number and title of this funding opportunity
The letter of intent should be sent to:
Xingzhu Liu, M.D., Ph.D.
FIRCA-BSS Program Officer
Division of International Training and Research
Fogarty International Center (FIC)
Building 31, Room B2C39
31 Center Drive, MSC-2220
Bethesda, MD 20892-5475
Telephone: 301-496-1653
Email: [email protected]
The forms package associated with this FOA includes all applicable components, mandatory and optional. Please note that some components marked optional in the application package are required for application submission. Follow all instructions in the SF424 (R&R) Application Guide to ensure you complete all appropriate optional components.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
Individuals are required to comply with the instructions for the Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, and Genome Wide Association Studies (GWAS) as provided in the SF424 (R&R) Application Guide.
Appendix
Do not use the appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide , with the following modifications:
Foreign (non-US) organizations must follow policies described in the NIH Grants Policy Statement, and procedures for foreign organizations described throughout the SF424 (R&R) Application Guide.
Part I. Overview Information contains information about Key Dates. Applicants are encouraged to submit in advance of the deadline to ensure they have time to make any application corrections that might be necessary for successful submission.
Organizations must submit applications via Grants.gov, the online portal to find and apply for grants across all Federal agencies. Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration.
Applicants are responsible for viewing their application in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.
This initiative is not subject to intergovernmental review.
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
Allowable costs include: purchases of supplies, equipment and technical assistance for the LMIC site; salary support or consultant fee for the LMIC collaborator/PD/PI; and travel for the high income country (HIC) and LMIC collaborators and their research associates as justified by the needs of the collaborative research. If the NIH funded PD/PI submits a detailed formal plan for extended teaching and consultation at the LMIC site, additional travel costs for this purpose may be budgeted.
Awards are made to the PD s/PI’s institution to support a collaborative research project that will be carried out mainly at the LMIC collaborator s/PD s/PI’s research site. The major portion (at least 70%) of the funds and items purchased with these funds must be used at the LMIC site to support this research in accordance with the following allowed budget allocations:
Applications must be submitted electronically following the instructions described in the SF 424 (R&R) Application Guide. Paper applications will not be accepted.
Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically.
Important
reminders:
All PD/PIs must include their eRA Commons ID in the Credential
field of the Senior/Key Person Profile Component of the SF 424(R&R)
Application Package. Failure to register in the Commons and to include a
valid PD/PI Commons ID in the credential field will prevent the successful
submission of an electronic application to NIH.
The applicant organization must ensure that the DUNS number it provides on the
application is the same number used in the organization’s profile in the eRA
Commons and for the Central Contractor Registration (CCR). Additional
information may be found in the SF424 (R&R) Application Guide.
See more tips for avoiding common
errors.
Upon receipt, applications will be evaluated for completeness by the Center for Scientific Review, NIH. Applications that are incomplete will not be reviewed..
Other Submission Requirements:
Project Summary Abstract: In addition to the standard application instructions, for FIRCA applications from the NIH funded PD/PI’s institution, please include in this section the name of the LMIC collaborator, collaborator country and institution, and the companion grant number and project period (e.g., This research will be done primarily in Peru at Lima University in collaboration with Jorge Smith, with the companion grant being R01HL00000, 9-30-2006 to 9-30-2011 ). A concise description of sister grant aims should be provided here. For applications from previous FIRCA collaborator’s Institution in the LMIC, please include the FIRCA grant number, and project period.
Attachment: For FIRCA all applications, upload a letter of support (on institutional letterhead, and in Other Research Plan Sections) from the LMIC collaborator/PD/PI’s institution, confirming the investigator’s role in the project. Please include full contact information, including email address and telephone and fax numbers for the LMIC collaborator/PD/PI. Provide a statement in the same letter, confirming the LMIC organization’s willingness to comply with all pertinent U.S. Federal regulations and policies. Refer to the following NIH Grants Policy Statement regarding grants to foreign institutions (http://grants.nih.gov/grants/policy/nihgps_2010/nihgps_ch16.htm#_Toc271265275 )
Project/Performance Site Locations: Provide the full name and address of the LMIC institution where the research will be performed (or the collaborating U.S. institution if the application is from a LMIC institution).
Research Strategy Plan: Preliminary Studies/ Progress Report: All FIRCA applications should include, at the beginning of this section, a description of the nature of the proposed collaboration. Also discuss any relevant previous collaborative arrangement(s).
Research Strategy Plan: At the end of this section, outline the proposed contributions of the NIH-funded investigator and the LMIC collaborator/PD/PI to the study. An optional plan for extended teaching and consultation by the NIH funded collaborator at the LMIC site may be included. In this case please outline the proposed curriculum for teaching and consultation activities for up to three months.
Applicants are required to follow the instructions for post-submission materials, as described in NOT-OD-10-115.
Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.
The R03 small research grants program supports discrete, well-defined projects that realistically can be completed in two years and that require limited levels of funding. Because the research project usually is limited, an R03 grant application may not contain extensive detail or discussion. Accordingly, reviewers should evaluate the conceptual framework and general approach to the problem. Appropriate justification for the proposed work can be provided through literature citations, data from other sources, or from investigator-generated data. Preliminary data are not required, particularly in applications proposing pilot or feasibility studies.
Reviewers will provide an overall impact/priority score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).
Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Significance
Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field
Investigator(s)
Are the PD/PIs, collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
If the LMIC collaborator is submitting as the PD/PI, is she/he able to undertake and direct the continuation of the research efforts independently but with some level of collaboration with the original (or new) FIRCA collaborator as justified by the needs of the research? How will this award continue to enhance the LMIC PD/PI’s research and career development and help her/him towards achieving a position of scientific leadership in her/his home country and field?
Innovation
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed? Does the project make use of unique or special expertise, resources, circumstances, or environment at the LMIC site to frame or address the research question? Does the project propose innovative or special ways to incorporate capacity building or training into the research program at the LMIC site?
Approach
Are the overall strategy, methodology, and analyses
well-reasoned and appropriate to accomplish the specific aims of the project?
Are potential problems, alternative strategies, and benchmarks for success
presented? If the project is in the early stages of development, will the
strategy establish feasibility and will particularly risky aspects be
managed?
If the project involves clinical research, are the plans for 1) protection of
human subjects from research risks, and 2) inclusion of minorities and members
of both sexes/genders, as well as the inclusion of children, justified in terms
of the scientific goals and research strategy proposed?
For applications designating multiple PDs/PIs, does the Leadership Plan ensure that there will be sufficient coordination and communication among the PDs/PIs? Are the administrative plans for the management of the research project appropriate, including plans for resolving conflicts?
Environment
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements? Has the LMIC collaborator/PD/PI’s home institution made a convincing commitment (e.g., provided a research/academic appointment and salary support)? Are the resources necessary to perform the research available or obtainable?
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact/priority score, but will not give separate scores for these items.
Research Capacity Building
How will the award contribute to building needed research capacity/capability at the LMIC site? For new FIRCA collaborations does the collaboration have the potential to enhance the research capability of the LMIC collaborator/PD/PI and the LMIC site? Does the research constitute a substantial scientific endeavor of the LMIC collaborator/PD/PI, including creative and scientific input to the research proposal? If the PD/PI is from the LMIC site, how will the award contribute to advancing his/her research and career, research at the PD s/PI’s institution and the field of research in the PD/PI’s country?
Protections for Human Subjects
For research that involves human subjects but does
not involve one of the six categories of research that are exempt under 45 CFR
Part 46, the committee will evaluate the justification for involvement of human
subjects and the proposed protections from research risk relating to their
participation according to the following five review criteria: 1) risk to
subjects, 2) adequacy of protection against risks, 3) potential benefits to the
subjects and others, 4) importance of the knowledge to be gained, and 5) data
and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or
more of the six categories of research that are exempt under 45 CFR Part 46,
the committee will evaluate: 1) the justification for the exemption, 2) human
subjects involvement and characteristics, and 3) sources of materials. For
additional information on review of the Human Subjects section, please refer to
the Human Subjects Protection and Inclusion
Guidelines.
Inclusion of Women, Minorities, and Children
When the proposed project involves clinical research, the committee will evaluate the proposed plans for inclusion of minorities and members of both genders, as well as the inclusion of children. For additional information on review of the Inclusion section, please refer to the Human Subjects Protection and Inclusion Guidelines.
Vertebrate Animals
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Biohazards
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
Resubmissions
For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.
Renewals
Not Applicable.
Revisions
For Revisions, the committee will consider the appropriateness of the proposed expansion of the scope of the project. If the Revision application relates to a specific line of investigation presented in the original application that was not recommended for approval by the committee, then the committee will consider whether the responses to comments from the previous scientific review group are adequate and whether substantial changes are clearly evident.
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact/priority score.
Applications from Foreign Organizations
Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.
Select Agent Research
Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Resource Sharing Plans
Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) Data Sharing Plan; 2) Sharing Model Organisms; and 3) Genome Wide Association Studies (GWAS).
Budget and Period of Support
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) (assignments will be shown in the eRA Commons), in accordance with NIH peer review policy and procedures, using the stated review criteria.
As part of the scientific peer review, all applications will:
Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications . Following initial peer review, recommended applications will receive a second level of review by the FIC Advisory Board . The following will be considered in making funding decisions:
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons.
Information regarding the disposition of applications is available in the NIH Grants Policy Statement.
If the application is under consideration for funding, NIH
will request "just-in-time" information from the applicant as
described in the NIH Grants
Policy Statement.
A formal notification in the form of a Notice of Award (NoA) will be provided
to the applicant organization for successful applications. The NoA signed by
the grants management officer is the authorizing document and will be sent via
email to the grantee business official.
Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection
of an application for award is not an authorization to begin performance. Any
costs incurred before receipt of the NoA are at the recipient's risk. These
costs may be reimbursed only to the extent considered allowable pre-award costs.
Any application awarded in response to this FOA will be subject to the DUNS, CCR Registration, and Transparency Act requirements as noted on the Award Conditions and Information for NIH Grants website.
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.
Cooperative Agreement Terms and Conditions of Award
Not Applicable
When multiple years are involved, awardees will be required to submit the Non-Competing Continuation Grant Progress Report (PHS 2590) annually and financial statements as required in the NIH Grants Policy Statement.
A final progress report, invention statement, and Financial Status Report are required when an award is relinquished when a recipient changes institutions or when an award is terminated.
The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.FSRS.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.
We encourage inquiries concerning this funding opportunity
and welcome the opportunity to answer questions from potential applicants.
Applicants can obtain information and research interests for each of the
sponsoring ICs listed on the first page of this announcement at their websites,
or by contacting the IC program contact listed in Section VII, Agency
Contacts. Some of the participating ICs have provided additional statements
of interest:
Grants.gov
Customer Support (Questions regarding Grants.gov registration and
submission, downloading or navigating forms)
Contact Center Phone: 800-518-4726
Email: [email protected]
GrantsInfo (Questions regarding application instructions and
process, finding NIH grant resources)
Telephone 301-710-0267
TTY 301-451-5936
Email: [email protected]
eRA Commons Help Desk(Questions regarding eRA Commons
registration, tracking application status, post submission issues)
Phone: 301-402-7469 or 866-504-9552 (Toll Free)
TTY: 301-451-5939
Email: [email protected]
FIC/NIH:
Xingzhu Liu, M.D., Ph.D.
FIRCA-BSS Program Officer
Division of International Training and Research
Fogarty International Center (FIC)
National Institutes of Health
Building 31, Room B2C39
31 Center Drive, MSC 2220
Bethesda, MD 20892-2220
Telephone: 301-496-1653
Fax: 301-402-0779
Email: [email protected]
NCI/NIH:
Michele Bloch, M.D., Ph.D.
Tobacco Control Research Branch
Behavioral Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute (NCI)
National Institutes of Health
6120 Executive Boulevard, EPN Room 4044, MSC 7337
Bethesda, MD 20892-7337 (for U.S. Postal Service express or regular mail)
Rockville, MD 20852 (for non-USPS courier/express delivery)
Telephone: 301-402-5284
Fax: 301-496-8675
Email: [email protected]
NIA/NIH:
Dallas W. Anderson, Ph.D.
Program Director, Population Studies
Dementias of Aging Branch
Division of Neuroscience
National Institute on Aging (NIA)
National Institutes of Health
7201 Wisconsin Avenue, MSC-9205
Gateway Building, Suite 350
Bethesda, MD 20892-9205
Telephone: 301-496-9350
Fax: 301-496-1494
Email: [email protected]
NIAAA/NIH
Peggy
Murray,
PhD.
Senior Advisor for International
Research
National
Institute on Alcohol Abuse and Alcoholism (NIAAA)
5635
Fishers Lane,
room 2013, Rockville, MD 20852
Phone:
301-443-2594
Email: [email protected]
NIDCD/NIH:
Lana Shekim, Ph.D.
Director, Voice and Speech Programs
Division of Scientific Programs
National Institute on Deafness and Other Communication Disorders (NIDCD)
National Institutes of Health
6120 Executive Boulevard, EPS-400C, MSC 7180
Bethesda, MD 20892-7180
Telephone: 301-496-5061
Fax: 301-402-6251
Email: [email protected]
NIDCR/NIH:
Jason Wan, Ph.D.
Integrative Biology and Infectious Diseases Branch
Division of Extramural Research
National Institute of Dental and Craniofacial Research (NIDCR)
National Institutes of Health
6701 Democracy Boulevard, Room 648, MSC 4878
Bethesda, MD 20892-4878
Telephone: 301-594-9898
Fax: 301-480-8319
Email: [email protected]
NIDA/NIH:
Steven W. Gust, Ph.D.
Director, NIDA International Program
National Institute on Drug Abuse (NIDA)
National Institutes of Health
31 Center Drive, MSC 8010
Building 31, Room 1B59
Bethesda, MD 20892-8010
Telephone: 301-443-6480
Fax: 301-443-9127
Email: [email protected]
Dan Gerendasy, Ph.D.
Scientific Review Administrator
International Cooperative Programs
Center for Scientific Review
6701 Rockledge Drive, Room 5132
Bethesda, MD 20892-7843 (use ZIP 20817 for overnight mail)
Telephone: 301-594-6830
Fax: 301-480-1677
Email: [email protected]
FIC/NIH:
Angela Smith
Grants Management Specialist
Fogarty International Center (FIC)
31 Center Drive, MSC-2022
Building 31, Room B2-C29
Telephone: 301-402-9592
Email:[email protected]
NCI/NIH:
Crystal Wolfrey
Deputy Director
Office of Grants Administration
National Cancer Institute (NCI)
National Institutes of Health
6120 Executive Blvd., Suite 243
Bethesda, MD 20892-7150
Telephone: 301-496-8634
Email: [email protected]
NIA/NIH:
Linda C. Whipp
Grants Management Officer
National Institute on Aging (NIA)
National Institutes of Health
7201 Wisconsin Avenue, MSC-9205
Gateway Building, Suite 2N212
Bethesda, MD 20892-9205
Bethesda, MD 20892-9205
Telephone: 301-402-7731
Email: [email protected]
NIAAA/NIH:
Judy Fox
Chief, Grant Management
Branch
National Institute on Alcohol
Abuse and Alcoholism (NIAAA)
Telephone: 301-443-4704
Email: [email protected]
NIDCD/NIH:
Christopher Myers
Grants Management Officer
National Institute on Deafness and other Communication
Disorders (NIDCD)
National Institutes of Health
6120 Executive Blvd., Suite 400B, MSC-7180
Bethesda, MD 20892-7180
Telephone: 301-435-0713
Email: [email protected]
NIDCR/NIH:
Mary Greenwood
Grants Management Officer
National Institute on Dental and Craniofacial Research
(NIDCR)
National Institutes of Health
6701 Democracy Blvd., Room 658, MSC-4878
Telephone: 301-594-4808
Email: [email protected]
NIDA/NIH:
Carol Alderson
Grants Management Branch
National Institute on Drug Abuse (NIDA)
National Institutes of Health
6001 Executive Blvd., Room 4128, MSC-9541
Rockville, MD 20892-9541
Telephone: 301-594-5614
Email: [email protected]
Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Parts 74 and 92.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
| ||||||
|
|
|
Department of Health and Human Services (HHS) |
|
|||
|
NIH... Turning Discovery Into Health® |
||||||